The aim of this report is to assess the added benefit of crizotinib in patients with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC)
http://ift.tt/2seTuZW
Πέμπτη 15 Ιουνίου 2017
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Publication date: January–February 2018 Source: Materials Today, Volume 21, Issue 1 Author(s): David Bradley http://ift.tt/2BP...
-
http://ift.tt/2sxENoo
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου